In a significant regulatory achievement, Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection conducted by Brazil’s health regulatory authority, ANVISA, for its API-III manufacturing facility located at Karakhadi, Gujarat.
According to the company’s regulatory filing submitted to stock exchanges on May 15, 2026, the inspection was carried out from May 11 to May 15, 2026, and concluded without any observations.
The inspection covered multiple Active Pharmaceutical Ingredients (APIs), and the clean outcome is expected to strengthen the company’s presence in international regulated markets, especially in Latin America. Receiving approval without observations is considered an important milestone for pharmaceutical manufacturers, as it reflects strong compliance with global quality and manufacturing standards.
ANVISA is regarded as one of the stricter pharmaceutical regulatory agencies globally, and successful inspections enhance export opportunities for Indian pharmaceutical companies in the Brazilian market.
Industry experts believe such regulatory clearances can support future API business growth and reinforce confidence among global customers seeking reliable supply partners from India’s pharmaceutical sector.
